Office of Medical Assistance Programs
State of Oregon
Drug Use Review Board
Meeting Minutes
September 9, 2003

I. Call to order

a. Members present: Gregory Johnson, MD; John Muench, MD, MPH; Robert Ingle, MD; Patrick Bowman, RPh; Rickland Asai, DMD; Robert Mendelson, MD; Gerald Fairbanks, RPh and Raymond Lee, MD. Members absent: Dean Haxby, PharmD, Sharon Leigh, PharmD, Cliff Singer, MD and Christina Heinrich, PharmD. Staff present: Kathy Ketchum (OSU), Dan Hartung (OSU), Cindy Yeh (OSU), Rose-Ellen Hope (FHSC) and Tom Drawbaugh (OMAP). Guests preasent: Scott Oswald (OSU pharmacy student), Jim Goddard (Shire), Jonell Zanta (Shire), Dennis Sagendorf (Purdue), Keith Ross (Sepracor), Tom Burns (GSK), Denise Jepson (Wyeth), Pat Wisemen (MedImmune) and Dwane Hanson (Wyeth).

b. A quorum was present and meeting was called to order at 2:10 PM by Chairman Gregory Johnson.

c. The minutes were approved with no corrections and agenda was approved with additions to the agenda packet materials and addition of "New Business" item to select meeting dates for 2004.

d. The Conflict of Interest Declaration was reviewed and renewed.

e. There was no public comment.

II. Old Business

a. DEA/OMAP provider number cross-walk

Ms. Ketchum reported that this was not possible because OMAP does not collect DEA information. Other options to reduce the lack of provider identification on drug claims were discussed.

Action: Ms. Ketchum to investigate the feasibility of using the provider license number.

b. Antidepressant Management

Ms. Ketchum reported that DHS will be implementing a mental health pharmacy management program consistent with the DUR Board recommendations from the May 2003 meeting. It will be educational and voluntary in nature. Prior authorization is not considered an option at this time. A budget note directs DHS to work with a specific outside contractor. The Attorney General's office is investigating the procurement issues related to this directive.

c. Triptan quantity limits

Ms. Ketchum reported that OMAP delayed decision on this item until the Health Resources Commission had completed its review of the class. This

was completed in June. OMAP has decided to move forward with implementation of triptan quantity limits consistent with DUR Board recommendations. Implementation date is yet to be determined.

d. Synagis drug use evaluation

Dr. Hartung presented his literature review and use evaluation of Synagis use in the OHP open-card population. Current utilization is generally within the AAP guidelines. Approximately 3% were older than 24 months and 7% were outside of the RSV season date range.

III. Reports

a. Drug Cost PMPM Report

The DUR Board reviewed the report.

b. Generic Use Report

The DUR Board reviewed the report.

c. ProDUR Alert Report by Class (tabled)

d. ProDUR Report (tabled)

e. RetroDUR Report

Ms. Hope reported that generally there are fewer letters and better response rates, likely due to better criteria. The DUR Board reviewed potential criteria regarding antidepressant use in children, risperidone use in the elderly and methadone dosing.

Action: The DUR Board recommended that RetroDUR to letter on proposed criteria.

f. Education Report

Ms. Ketchum reported the College did not produce a newsletter in June or July. In August the medication overuse review was published. Future articles include: the new evidence reports from the Health Resources Commission, a review of the new hypertension treatment guidelines, a review of the drug therapy for senile dementia and perhaps a review of Flumist and Xolair. The College will also assist OMAP by producing "change forms" to educate providers about the PMPDP.

g. HRC Report

Ms. Ketchum reported that evidence reports for four additional classes are complete. These include the oral hypoglycemics, skeletal muscle relaxants, triptans and urinary incontinence drugs. The recommended benchmark drugs are glyburide, cyclobenzaprine, baclofen, rizatriptan and oxybutinin. The original four classes went through an updated review. The only major change

in the original findings were that atorvastatin and fluvastatin now have health outcome data. ACE inhibitors, beta-blockers and calcium channel blockers are starting the evidence review process.

h. Pharmacy Program Update

Mr. Drawbaugh reviewed the program changes since May that included a pharmacy reimbursement reduction to AWP-15%, a requirement to bill other insurances prior to Medicaid, a prior-authorization requirement for branded products and a prior-authorization for gabapentin. Policies scheduled for implementation include managed care coverage of gabapentin, repeal of the enhanced exception process for the PMPDP, mandated payment for drugs dispensed by rural health clinics, prior authorization for any drug over 15 drugs in a 6 month period, increase mail order market share to 15-18%, and pursuit of supplemental rebates. Legislative mandates of potential interest include the expansion of the Senior Drug Program to include HIV and transplant patients, a move to retain "standard clients" that depends on passage of the tax measure, move the prioritized list up 30 lines and develop an RFP for a PBM/ PBA to include the OHP managed care plans and the open-card program.

IV. New Business

a. Growth Hormone PA Criteria Review

Dr. Yeh presented a literature review and proposed changes to the GH PA criteria.

Action: The DUR Board recommended that the GH PA Criteria be updated to the proposed criteria presented.

b. New Drug Reviews

i. FH Clinical Alerts

The DUR Board reviewed the alerts. It was noted that one new drug (alfuzosin) is used for a below-the-line indication and will not be covered by the OHP open card program.

Action: These reports will no longer be presented to the Board after Jan. 1, 2004 because of recent legislation prohibiting the Board from reviewing drugs prior to approval.

ii. Flumist

Ms. Ketchum presented the review.

Action: The DUR Board recommended that PA criteria be developed to insure high risk patients and patients with compromised immune systems continue to receive the inactivated IM vaccine.

iii. Emend

Dr. Yeh presented the review.

Office of Medical Assistance Programs
State of Oregon
Drug Use Review Board
Meeting Minutes
September 9, 2003

Action: The DUR Board recommended that OHSU use criteria be brought before the Board and evaluated. The Board recommended use in the OHP open-card program be monitored closely.

iv. Xolair

Dr. Hartung presented the review.

Action: The DUR Board recommended that use of this agent be monitored closely.

c. Annual Report

The DUR Board reviewed the report.

d. 2004 Meeting Dates

Action: Meeting dates for 2004 are: Tuesdays at 2-5 PM on February 24, May 25, September 14 and November 30.

Meeting was adjourned at 4:45 PM by Chairman Gregory Johnson.

Minutes respectfully submitted by Kathy Ketchum.